紫杉醇联合奥沙利铂和卡培他滨治疗晚期胃癌的临床观察  

Clinical observation of advanced gastric cancer treated with paclitaxel plus oxaliplatin and capecitabine

作　　者：陆锡燕 周长芳[1] 陈雷[1] 

机构地区：[1]南京鼓楼医院集团宿迁市人民医院肿瘤科,江苏宿迁223800

出　　处：《临床肿瘤学杂志》2010年第11期1023-1025,共3页Chinese Clinical Oncology

摘　　要：目的 评价紫杉醇联合奥沙利铂和卡培他滨（POX方案）治疗晚期胃癌的疗效和不良反应.方法 21例晚期胃癌患者均采用POX方案治疗：紫杉醇85mg/m2, 第 1、8天,静脉滴注;奥沙利铂 130 mg/m2, 第 1天,静脉滴注;卡培他滨 1000mg/m2分2次口服,第 1～14天, 21天为 1周期.2周期评价疗效.结果 全组21例均可评价疗效,其中PR 13例,SD 6 例, PD 2例, 客观有效率为61.9%;中位肿瘤进展时间为5.7个月,中位总生存期为11个月.不良反应主要为骨髓抑制、恶心呕吐和外周神经毒性.结论 紫杉醇联合奥沙利铂和卡培他滨治疗晚期胃癌疗效较好, 不良反应可耐受, 值得临床进一步研究.Objective To investigate the efficacy and toxicity of paclitaxel plus oxaliplatin and capecitabine （ POX regimen） chemotherapy in treatment of advanced gastric cancer （AGC）. Methods Twenty-one patients with advanced gastric cancer were treated with paclitaxel 85mg/m^2 intravenously on day 1 and day 8, oxaliplatin 130mg/m^2 intravenously on day 1, and capecitabine 1000mg/m^2 orally twice a day from day 1 to day 14. The chemotherapy regimen was repeated once every 3 weeks, and all patients received at least 2 cycles of chemotherapy. Results All 21 cases were available to evaluate effect. Among them, There was no complete response （CR）, 13 partial response （PR）, 6 stable disease （SD） and 2 progress disease （PD）. The overall response rate （RR） was 61.9%, time to progression was 5.7 months and median survival time was 11 months. The main toxicities were myelosuppression, nausea, vomiting, and neutropenia. Conclusion The study proves that paclitaxel plus oxaliplatin and capecitabine regimen is an effective and well tolerated treatment for AGC, which is worthy of further clinical research.

关 键 词：晚期胃癌 紫杉醇 奥沙利铂 卡培他滨 化学治疗 

分 类 号：R735.2[医药卫生—肿瘤]